Treatment of anemia due to chronic kidney disease with agents increasing erythropoietin (EPO) from erythropoietin producing cell (EPC) by inhibition of one of the enzymes causing degradation of hypoxia inducible factor (HIF) (HIF prolyl hydroxylase inhibitor (HIF-PHI)) is gaining popularity (Chen et al., 2022). The gene discussed is EPO; the disease is chronic kidney disease.